The purpose of the Developmental Research Program (DRP) is to fund promising projects by investigators whose current work may not focus exclusively on endometrial cancer, but who propose highly innovative translational studies of endometrial cancer that could become full SPORE projects or compete successfully for funding outside of the SPORE mechanism. The DRP provides a unique venue for making available significant financial support, and for demonstrating active institutional support, through a program that is rapidly responsive to new ideas or initiatives. Moreover, this program is rooted in a spirit of collaboration espoused by the SPORE investigators, who have an extensive track-record of bringing investigators from other disciplines into the field of endometrial cancer research. The strength of the Developmental Research Program rests in its ability to make available financial support and access all the critical expertise and resources within the entire SPORE, including SPORE Cores. This will allow us to develop important collaborative, multi-investigator, multi- institutional research projects with the support of innovative, investigator-initiated projects that have the potential to flourish into reliable and productive translational research projects for the SPORE. Pre-proposals in the form of 1 page letters of intent will be solicited by the Program, and applicants with pre-proposals that are highly competitive for the goals of this program will be invited to submit a full proposal for review. The DRP Directors will help investigators submitting proposals to formulate relevant translational research aims and plans, as many applicants may not have prior expertise in this type of research. This process will therefore be a major educational activity that is further anticipated to stimulate translational research in endometrial cancer and encourage the participation of both basic science researchers and clinical investigators in translational research. The DRP will be led by Thomas Burke, M.D., the founding Endometrial Cancer SPORE PI and current Vice President of the MD Anderson Cancer Network, and Wei Zhang, Ph.D., a Professor in the Department of Pathology with specific expertise in cancer biology, genomics, and construction of miRNA signaling networks. Russell Broaddus, M.D., Ph.D., SPORE Co-PI, will provide oversight to the DRP. The DRP is critical to the continued success of the SPORE, as shown by four former DRP awardees now involved as research project Co-PIs in this application, and a fifth is an important co-investigator on a SPORE project. Two other former DRP awardees will provide their scientific expertise by serving on the External Advisory Board.

Public Health Relevance

Developmental Research Program NARRATIVE The Developmental Research Program (DRP) will support innovative and scientifically sound projects that investigate questions pertaining to translational research in endometrial cancer. This program will encourage the recruitment of new investigators into the endometrial cancer research community and the development of innovative high-impact research that could expand into full projects for the Endometrial Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098258-15
Application #
10006201
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2019-09-01
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
15
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Bolivar, Ana M; Luthra, Rajyalakshmi; Mehrotra, Meenakshi et al. (2018) Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol :
Yuan, Xiaoyi; Lee, Jae W; Bowser, Jessica L et al. (2018) Targeting Hypoxia Signaling for Perioperative Organ Injury. Anesth Analg 126:308-321
Du, Di; Ma, Wencai; Yates, Melinda S et al. (2018) Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9:19704-19715
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Kim, Grace; Kurnit, Katherine C; Djordjevic, Bojana et al. (2018) Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31:1553-1559
Yoo, Jung-Yoon; Kang, Hee-Bum; Broaddus, Russell R et al. (2018) MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer 18:605
Yuan, Ying; Lin, Ruitao; Li, Daniel et al. (2018) Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930
Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490
Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699

Showing the most recent 10 out of 578 publications